Recon: FDA Oks J&J’s Talvey for blood cancer; Novo agrees to buy obesity drugmaker Inversago for $1B
ReconJason Scott
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy